Matritech (NASDAQ - NMPS) Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Matritech (NASDAQ - NMPS)

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: William J. Leiby who wrote (491)	10/2/1997 11:03:00 PM
From: John McCarthy	of 849

Bill Thanks for the info. Then things will unfold something like ... Timeline --------------- Approved Colon test ($100 mil. mkt) by mid '98. Approved Cervical test ($xxx mil. mkt) by mid '99. Approved Breast test ($xxx mil. mkt) by mid '00 While I admittedly have not followed this company as closely as some others, the perception that I had formulated sometime ago was that the Bladder market was a difficult one to enter (really 2 markets) but the Colon market would be a no brainer i.e. there is nothing worthwhile out there now. On the other hand, I can't talk to the Cervical market because I am confused as to how this test 'fits in' against the likes of the ThinPrep test (CYTC) , Papnet (NSIX) and the 1 or 2 other companies in this area. Finally - for now - I am just assuming that the breast cancer market will be huge and they will get a major share of it dependent on their products performance i.e. ability to call it out very early. If I have missed the mark on 1 or more points, or if you see it differently, please advise. Regards, John

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next